Henry Schein (HSIC) continues to make significant headlines. The biotech company is poised to beat earnings estimates again, with its valuation and ratings being reassessed due to changes in board structure and company leadership. Citigroup has initiated coverage of HSIC with a buy recommendation, which has led to an increase in stock trading. Despite facing certain risks, HSIC is being termed a strong value stock and a top growth stock for long-term investors. The company’s recent board overhaul following Bergman’s exit is said to alter its investment potential. However, investors are reacting differently to these changes. Meanwhile, HSIC has seen its share price decrease by 9.4% since the last earnings report, creating intrigue around its capability to rebound. The biotech firm projects robust Q4 sales results, driven mainly by Specialty Products. With Frederick M. Lowery as its newly appointed CEO, HSIC is expected to continue emphasizing margin improvement despite a five-year earning decline. Despite a cautious outlook by some, the firm remains a popular buy within the market.
Henry Schein HSIC News Analytics from Mon, 14 Jul 2025 07:00:00 GMT to Sat, 18 Apr 2026 18:54:01 GMT -
Rating 5
- Innovation 1
- Information -3
- Rumor -8
